Pfizer Inc., a global biopharmaceutical company with a market capitalization of around $146 billion, is focused on researching, developing, and marketing medicines and vaccines worldwide. Despite challenges post-pandemic, Pfizer is forging ahead with innovative treatments. While its stock has struggled recently, up only 3.2% in the last three months, Pfizer remains optimistic about its expanding pipeline. Concerns about patent expirations and declining COVID-19 product sales have weighed on Pfizer’s shares, but recent FDA approval of a new combination treatment for bladder cancer has sparked a 2.6% stock jump. Analysts still rate Pfizer as a “Moderate Buy” with potential upside.

Read more at Barchart: Is Pfizer Stock Underperforming the Dow?